SBC Medical Starts Building a DNA‑Methylation Test to Gauge Biological Age

IRVINE, Calif. — SBC Medical Group Holdings (Nasdaq: SBC) announced today that its AI‑focused arm, SBC AI Longevity Innovation, has begun internal work on a test that reads DNA methylation patterns to estimate a person’s biological age. The effort leans heavily on the research platform built by the Waqoo Group—a Tokyo‑listed firm and its Japan‑based subsidiary, Cell Pro Japan.

The goal is simple, yet ambitious: give folks a “real‑age” number that reflects how their bodies are aging, not just the number of candles on the birthday cake. That number could become a personal baseline, helping users track how diet, stress, sleep, or exercise actually shift their biology over months and years.

In recent years, the health‑care conversation has moved from trying to add years to life toward trying to add life to years. Investors, scientists and policymakers are all pouring resources into the longevity space, and SBC Medical sees the emerging market as a natural next step for its expanding suite of services.

Industry analysts estimate the global longevity market will balloon from roughly $800 billion in 2025 to almost $2 trillion by 2035. Japan, with its rapidly aging population, is already positioning itself as a testing ground for health‑span technologies, and SBC hopes to ride that wave.

What makes DNA methylation a compelling target? Unlike the static DNA sequence we inherit, methylation marks are dynamic—they flip on or off in response to lifestyle, environment, and stress. In other words, they act like a molecular diary of our daily choices. Recent breakthroughs, such as the 2025 study that could infer the age of 11 different organs from a single blood draw, have shown just how powerful these epigenetic clocks can be.

By marrying the Waqoo Group’s regenerative‑medicine know‑how with SBC Medical’s extensive clinic network and patient‑experience expertise, the company believes it can move the test from the lab bench to a scalable, consumer‑friendly product.

“We’re not just chasing a novelty metric,” said a spokesperson for SBC AI Longevity Innovation. “We want a reliable, repeatable tool that clinicians and individuals can use side‑by‑side with traditional health metrics to make smarter, data‑driven decisions.”

The development roadmap is still early, but the team plans to run pilot studies with existing SBC patients, refine the algorithm with AI, and eventually seek regulatory clearance for a commercial launch. If successful, the test could become a new cornerstone of preventive medicine—something you check as regularly as blood pressure or cholesterol.

As the science of epigenetic aging matures, SBC Medical hopes its test will demystify the invisible processes of aging, turning them into actionable information that anyone can understand and act upon.